FDA Warning Letter Issued to Novo Nordisk Signals Expanding FDA Inspection Focus Beyond Traditional GMP Operations

May 13, 2026

Key Takeaways

FDA issued a Warning Letter to Novo Nordisk following a pharmacovigilance inspection involving adverse event reporting processes
FDA cited concerns involving delayed reporting, inadequate investigations, and pharmacovigilance procedure deficiencies
The Warning Letter involved products containing semaglutide and liraglutide
FDA inspections are increasingly expanding beyond traditional GMP manufacturing operations
Pharmacovigilance, postmarket surveillance, vendor oversight, and enterprise-wide quality systems are becoming major FDA inspection focus areas

The FDA issued a Warning Letter to Novo Nordisk on March 5, 2026, following a Postmarketing Adverse Drug Experience (PADE) inspection conducted at the company’s Plainsboro, New Jersey facility. The inspection occurred between January and February 2025 and focused on the company’s pharmacovigilance and adverse event reporting systems.

The Warning Letter highlights FDA’s growing focus on postmarket surveillance, safety reporting, and enterprise-wide quality oversight in addition to traditional GMP manufacturing inspections.

FDA Identified Concerns With Adverse Event Reporting Procedures

According to FDA, Novo Nordisk failed to establish and maintain adequate written procedures for the surveillance, receipt, evaluation, investigation, and reporting of postmarketing adverse drug experiences associated with multiple products, including semaglutide-containing therapies.

FDA cited several concerns, including:

failure to submit serious and unexpected adverse event reports within required 15-day timelines
cancellation or rejection of adverse event cases based on assumptions that products were not related to reported events
inadequate follow-up investigations involving serious adverse events
deficiencies involving pharmacovigilance contractor oversight
weaknesses in adverse event quality systems and reporting procedures

FDA emphasized that companies are required to evaluate and report adverse events regardless of whether the reporter believes the product caused the event.

FDA Inspections Are Expanding Beyond Traditional GMP Operations

This Warning Letter serves as another indication that FDA inspections increasingly extend beyond manufacturing floor compliance activities.

Historically, FDA inspections heavily focused on:

GMP compliance
aseptic processing
laboratory controls
contamination control
data integrity
validation
batch record review

However, modern FDA inspections are increasingly evaluating:

pharmacovigilance systems
adverse event reporting workflows
complaint handling systems
digital quality systems
vendor oversight
global escalation procedures
enterprise-wide quality governance
postmarket surveillance programs

For pharmaceutical, biologics, and medical device companies, inspection readiness is becoming an increasingly cross-functional responsibility.

Why Pharmacovigilance Inspection Readiness Matters

As GLP-1 therapies, biologics, peptides, gene therapies, and other complex drug products continue expanding globally, FDA expectations surrounding safety monitoring and adverse event reporting are likely to intensify.

FDA investigators may review:

adverse event intake procedures
medical review documentation
signal detection systems
escalation timelines
complaint investigations
vendor oversight activities
electronic safety databases
SOP effectiveness
documentation consistency

Organizations relying heavily on contractors or third-party pharmacovigilance providers may face additional regulatory scrutiny involving oversight and quality management responsibilities.

Novo Nordisk Response to FDA Findings

Novo Nordisk publicly stated that the company initiated corrective actions following the inspection observations and Warning Letter.

Reported corrective actions included:

SOP revisions
strengthened pharmacovigilance oversight
internalization of certain safety intake functions
retrospective reviews of adverse event cases
procedural improvements involving reporting workflows

FDA indicated it would continue evaluating the adequacy and sustainability of corrective actions.

Final Thoughts

The Novo Nordisk Warning Letter may become another significant example of FDA’s evolving inspection strategy and expanding focus on enterprise-wide quality systems.

For regulated industry, inspection readiness increasingly involves more than manufacturing operations alone.

Organizations may need stronger alignment across:

Quality Assurance
Regulatory Affairs
Pharmacovigilance
Clinical Operations
Supply Chain
Digital Systems
Executive Leadership

As FDA inspections continue evolving, companies with integrated quality governance and robust postmarket surveillance systems may be better positioned to manage increasing regulatory expectations.

Frequently Asked Questions

Why did FDA issue a Warning Letter to Novo Nordisk?

FDA issued the Warning Letter following a pharmacovigilance inspection that identified concerns involving adverse event reporting procedures, investigation processes, and quality system oversight.

What products were involved in the Novo Nordisk Warning Letter?

The Warning Letter involved products containing semaglutide and liraglutide, including widely used GLP-1 therapies.

What is a PADE inspection?

A PADE inspection is a Postmarketing Adverse Drug Experience inspection focused on evaluating a company’s pharmacovigilance systems, adverse event reporting procedures, and postmarket surveillance activities.

Are FDA inspections expanding beyond GMP manufacturing operations?

Yes. FDA inspections increasingly involve pharmacovigilance, digital systems, complaint handling, postmarket surveillance, and enterprise-wide quality oversight.

Why is pharmacovigilance becoming more important during FDA inspections?

As complex biologics, GLP-1 therapies, and advanced drug products continue growing, FDA is placing greater emphasis on safety monitoring, adverse event reporting, and lifecycle quality management.